News
Recent Progress in Neuroendocrine Tumor Management
Has there been significant recent progress in the management of Neuroendocrine Tumors? NET specialist Jonathan R. Strosberg, MD of the H. Lee Moffitt Cancer Center in Tampa, Florida, says “unequivocally yes.” OncLive interviews Dr. …
READ MORENET Cancer Blogger and Advocate Winner in WEGO Health Activist Awards — Best in Show Community
Congratulations to Ronny Allan, @NETCancerBlog, upon winning the 2016 WEGO Health Activist Award for Best in Show Community. He was also a finalist in the Best in Show Blog category. The winners of the WEGO Health Activist Awards were announced on during…
READ MORECall for Nominations: 7th Annual Warner Advocacy Award
Novartis Oncology and The NET Alliance have announced that nominations are open for the 7th Annual Warner Advocacy Award. This annual award was established by Novartis in 2009 in honor of Monica Warner, who passed away in August 2009, to recognize the …
READ MOREJoin Our #14DaysOfGratitude
Check out our video Fighting NET Cancer with Grace & Gratitude and tell us about your appreciation for the things that matter most to you in the 14 days between NET Cancer Day and Thanksgiving. Tell us about your friends, family, support group members,…
READ MOREProject Zebra Report: Real-World Insights from the Carcinoid and NET Patient Community
In honor of Worldwide NET Cancer Awareness Day, we are pleased to release the first ever Project Zebra Report: Real-World Insights from the Carcinoid and Neuroendocrine Tumor Patient Community, a collaboration between our partner Self Care Catalysts…
READ MORECarcinoid/Neuroendocrine Cancer Specialist Announces Retirement from Medical Practice
Dr. Richard R.P. Warner, Director of the Center for Carcinoid and Neuroendocrine Tumors at Mount Sinai Hospital, has announced that he is retiring from his medical practice at Mount Sinai, as of November 1, 2016. Read more…
READ MOREStanford Health Care in California Launches Neuroendocrine Tumor Multidisciplinary Program
A new multidisciplinary Neuroendocrine Cancer center at Stanford Health Care in California has been established to improve the standard of care for NET patients and to advance the study of these rare diseases. Pamela Kunz, MD, is the Medical Director…
READ MORECarcinoid Cancer Foundation Announces Appointment of Edward M. Wolin, MD as Co-Medical Director and Board Member
Edward M. Wolin, MD, an internationally renowned neuroendocrine cancer specialist and medical oncologist, has been named Co-Medical Director and Board member of the Carcinoid Cancer Foundation (CCF) in White Plains, New York. Dr. Wolin is Director…
READ MOREFDA Approves New Diagnostic Imaging Agent to Detect Rare Neuroendocrine Tumors
Breaking news on June 1, 2016 from the U.S. Food and Drug Administration! The FDA has approved NETSPOT, “the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging.” …
READ MOREFDA Priority Review of Lexicon’s New Drug Application for Telotristat Etiprate Treatment for Carcinoid Syndrome
Lexicon Pharmaceuticals announced on May 31, 2016 that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for telotristat etiprate, an oral drug for the treatment of CARCINOID SYNDROME. “The FDA has granted…
READ MORE